

**PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT  
DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**Docket Number  
(Optional)  
GFI/103 US

First named inventor: Joseph Strauss

International (PCT) Application No: PCT/US03/41357      U.S. Application No.: Not Yet Assigned  
(if known)

Filed: December 23, 2003

Title: STEROID RECEPTOR MODULATION OF GENE EXPRESSION

Attention: PCT Legal Staff  
Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

**APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION**

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Proper Reply;
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

## 1. Petition fee

Small entity – fee \$ \_\_\_\_\_ (37 CFR 1.17(m)). Applicant claims small entity status.  
See 37 CFR 1.27.Other than small entity – fee \$ 1500.00 (37 CFR 1.17(m))

## 2. Proper Reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of a National Stage Filing under 35 U.S.C. § 371 (identify type of reply):

has been filed previously on \_\_\_\_\_.

is enclosed herewith.

Page 1 of 2

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be send to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

3112899.1

## 3. Terminal disclaimer with disclaimer fee

Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.

A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ \_\_\_\_\_ for a small entity or \$ \_\_\_\_\_ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

## 4. Statement: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**



Signature

July 11, 2005

Date

Gloria Fuentes

Typed or printed name

47,580

Registration Number, if applicable

FISH &amp; NEAVE IP GROUP

ROPES &amp; GRAY LLP

1251 Avenue of the Americas

New York, New York 10020

Address

(212) 598-9000

Telephone Number

Enclosures:  Response (See items listed below) Fee Payment Terminal Disclaimer Other (please identify):

Application Data Sheet (2 pages)

First Preliminary Amendment (8 pages)

Second copy of published International Application No. PCT/US03/41357

Transmittal of Sequence Listing in Computer Readable Form in Compliance with 37 C.F.R. §§ 1.821(E) and (F) (1 page)

Sequence Listing in paper copy (5 pages) and computer readable format

Statement Accompanying Sequence Listing (1 page)

Certificate of Express Mailing (1 page)